In 2023, the sales of Peptic Ulcer and GORD medicines in Canada stood at a value of USD PPP per capita of 17.7. From 2024 to 2028, the forecasted yearly values indicate a steady decline, with percentage decreases observed annually. Specifically, there is a notable decrease of approximately 2.3% from 2024 to 2025, followed by similar downward trends in subsequent years. Over the five-year forecast period, the average compound annual growth rate (CAGR) reflects a consistent decline in market sales, emphasizing a continued decrease in demand or price adjustments in this segment.
Future trends to watch for include potential advancements in medical treatments that may alter the current market dynamics. Additionally, emerging competitors and regulatory changes could influence sales trends. Monitoring consumer health behaviors and the introduction of alternative therapies will be crucial for market stakeholders.
